$MRK News Article - Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (?12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
https://marketwirenews.com/news-releases/merc...46222.html